Abstract:Regarding to the limitations of paclitaxel (PTX) in cancer treatment, PTX was extracted from Taxus chinensis and PTX nano-ultrasound contrast agents (NUCA) were prepared to investigate their impacts on proliferation and invasion of hepatocellular carcinoma (HCC) cells (HCCCs). The PTX extract was obtained through extraction and multi-step purification methods using Taxus chinensis as the source material and poly(lactic-co-glycolic acid)-carboxylic acid (PLGA-COOH) as the experimental material. A modified double emulsion solvent evaporation (DESE) method was employed to prepare paclitaxel-loaded PLGA NUCA (PLGA@PTX). The particle size distribution (PSD) and zeta potential (ZP) of PLGA@PTX were identified using a laser particle size (PS) analyzer, while the drug-loading capacity (DLC) and encapsulation efficiency (EE) of PTX in PLGA@PTX NUCA were evaluated using high-performance liquid chromatography (HPLC). The in vitro release rate (IVRR) of PTX from PLGA@PTX NUCA was also analyzed. HepG2 lines, a human HCC cell line, were grouped into four randomly: a blank control group (Blank), a PTX group, a blank nano-contrast agent group without PTX encapsulation (PLGA), and a PTX-loaded NUCA group (PLGA@PTX). In the Blank group, HepG2 lines were cultured conventionally for 12 hours, while PTX or PLGA@PTX was added to the PTX and PLGA@PTX groups, respectively, to achieve a required concentration (10 −7 mol/L) of PTX. An equal amount of PLGA nanoparticles was added to the PLGA group. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and Transwell were utilized to judge the impacts of PLGA@PTX nanoparticles on proliferation and invasion of HepG2 lines, respectively. Moreover, flow cytometry (FCT) was utilized to examine the influence of PLGA@PTX nanoparticles on cell cycle (CC) and apoptosis of HepG2 lines. The results revealed that the purity of the PTX extract was as high as 99.04±0.92%. The average PS of PLGA@PTX NUCA was (432.79±4.56) nm, with a surface potential of (−10.79±2.28) mV. Furthermore, the EE and DLC were (89.27±2.63) % and (9.03±0.29) %, respectively. The inhibition rate (IR) to HepG2 lines and cell invasion and the apoptotic rate (AR) in the PLGA@PTX group were much higher to those in the PLGA and PTX groups ( P <0.01, P <0.05). The ratio of G1/G0 phase in the CC was greatly lower in the PLGA@PTX group to the PLGA and PTX groups, showing obvious differences with ( P <0.05), while that of G2/M phase was higher ( P <0.05). These findings indicated that the prepared PLGA@PTX NUCA hindered the proliferation and invasion of HepG2 lines and induced CC arrest at the G2/M phase and apoptosis.

Paclitaxel poly lactide-co-glycolic acid nanoparticles inhibit human hepatocellular carcinoma cells HepG2

In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.

Development And Evaluation Of A Novel Tpgs-Mediated Paclitaxel-Loaded Plga-Mpeg Nanoparticle For The Treatment Of Ovarian Cancer

Effects of Ultrasound Contrast Agent-Encapsulated Paclitaxel Extract on the Proliferation and Invasion Ability of Hepatocellular Carcinoma Cells

The Inhibitory Effect of Paclitaxel Nanoparticles on Ovarian Cancer Xenografts and Lymphatic Targeting

Preparation of thermosensitive liposomes containing paclitaxel and their anticancer effect

Human serum albumin-bound paclitaxel nanoparticle inhibits cervical carcinoma cell proliferation and oxidative damage through CYP3A4 and CYP2C8

Preparation of paclitaxel loaded PLGA microspheres and its efficacy in Hep-2 laryngeal squamous cell carcinoma-bearing nude mice

The Anti-Tumor Effects of Lung Cancer-Targeting Long-Circulating Paclitaxel-Containing Liposomes

Anti-tumor Activity of Biodegradable Polymer-Paclitaxel Conjugate Micelles on H22 Liver Cancer Mice Models

Effect Of Peg-Pdlla Polymeric Nanovesicles Loaded With Doxorubicin And Hematoporphyrin Monomethyl Ether On Human Hepatocellular Carcinoma Hepg2 Cells In Vitro

Paclitaxel Nanoparticle Inhibits Growth of Ovarian Cancer Xenografts and Enhances Lymphatic Targeting.

N-acetylgalactosamine-decorated nanoliposomes for targeted delivery of paclitaxel to hepatocellular carcinoma

Preparation and Evaluation of Paclitaxel-Loaded Nanoparticle Incorporated with Galactose-Carrying Polymer for Hepatocyte Targeted Delivery.

Study on the Mechanism of Action of Paclitaxel-Loaded Polylactic-co-glycolic Acid Nanoparticles in Non-Small-Cell Lung Carcinoma Cells

Facile fabrication of TPGS-PCL polymeric nanoparticles for paclitaxel delivery to breast cancer: investigation of antiproliferation and apoptosis induction

Efficient Suppression of Liver Metastasis Cancers by Paclitaxel Loaded Nanoparticles in PDLLA-PEG-PDLLA Thermosensitive Hydrogel Composites

Preparation and anti-triple-negative breast cancer cell effect of a nanoparticle for the codelivery of paclitaxel and gemcitabine

Paclitaxel Liposome: Its in Vitro Killing Effect on Endometrial Carcinoma HEC-1A Cells

Experimental study on effects of intratumoral injection of paclitaxel-loaded poly (lactic-co-glycolic acid) micro-spheres on Hep-2 laryngeal squamous cell carcinoma xenografts in nude mice

Toxicity Assessment of PEG-PCCL Nanoparticles and Preliminary Investigation on Its Anti-tumor Effect of Paclitaxel-Loading